Study of NXP900 with lorlatinib for ALK-positive lung cancer
Treatments studied
This study tests a new drug called NXP900 in combination with lorlatinib for people with ALK-positive lung cancer who have already been treated with lorlatinib and tolerated it well. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have ALK-positive non-small cell lung cancer (NSCLC) that is advanced (unresectable, metastatic, or locally advanced).
- You must have previously taken lorlatinib as your first or second line of targeted therapy.
- You must have tolerated the dose of lorlatinib you took (or a higher dose) without severe side effects.
- You must not have known resistance mutations to lorlatinib or other targetable mutations (like MET, EGFR, or HER2) with approved therapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well and how safely the drug lorlatinib works in people with a certain type of advanced lung cancer (ALK-positive NSCLC) who have not had treatment for their advanced cancer yet. The goal is to see how effective it is in the real world.
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
This trial tests a targeted pill, lorlatinib, for people with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received previous treatment for advanced disease. It aims to see how well the drug works in this setting.
This trial tests lorlatinib as a treatment before surgery for people with a type of lung cancer called non-small cell lung cancer that has an ALK gene change (ALK-positive). The goal is to understand why some tumors respond and others may not, using advanced genetic tests.
This real-world study looks at how often lorlatinib causes side effects in the brain and nervous system in people with advanced ALK-positive non-small cell lung cancer. The goal is to better understand these risks so doctors can help patients manage them.
This trial tests a combination of two drugs for people with a specific type of advanced lung cancer that has a change in the ALK gene. The goal is to see if this combination works better than current treatments and to use a blood test to guide therapy.
Hear when a new ALK-positive Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.